434 related articles for article (PubMed ID: 29241186)
21. Protein delivery nanosystem of six-arm copolymer poly(ε-caprolactone)-poly(ethylene glycol) for long-term sustained release.
Duan J; Liu C; Liang X; Li X; Chen Y; Chen Z; Wang X; Kong D; Li Y; Yang J
Int J Nanomedicine; 2018; 13():2743-2754. PubMed ID: 29780245
[TBL] [Abstract][Full Text] [Related]
22. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
23. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
24. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
[TBL] [Abstract][Full Text] [Related]
25. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
26. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.
Korsak B; Almeida GM; Rocha S; Pereira C; Mendes N; Osório H; Pereira PMR; Rodrigues JMM; Schneider RJ; Sarmento B; Tomé JPC; Oliveira C
Int J Cancer; 2017 Oct; 141(7):1478-1489. PubMed ID: 28639285
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo.
Duan D; Wang A; Ni L; Zhang L; Yan X; Jiang Y; Mu H; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2018; 13():1831-1840. PubMed ID: 29606874
[TBL] [Abstract][Full Text] [Related]
28. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery.
Gou M; Zheng X; Men K; Zhang J; Zheng L; Wang X; Luo F; Zhao Y; Zhao X; Wei Y; Qian Z
J Phys Chem B; 2009 Oct; 113(39):12928-33. PubMed ID: 19736995
[TBL] [Abstract][Full Text] [Related]
29. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.
Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y
J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660
[TBL] [Abstract][Full Text] [Related]
30. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.
Sun B; Feng SS
Nanomedicine (Lond); 2009 Jun; 4(4):431-45. PubMed ID: 19505246
[TBL] [Abstract][Full Text] [Related]
32. A novel design of HA-coated nanoparticles co-encapsulating plasmid METase and 5-Fu shows enhanced application in targeting gastric cancer stem cells.
Yang W; Zhang H; Xin L
Biol Chem; 2018 Feb; 399(3):293-303. PubMed ID: 29016350
[TBL] [Abstract][Full Text] [Related]
33. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.
Liang G; Zhu Y; Ali DJ; Tian T; Xu H; Si K; Sun B; Chen B; Xiao Z
J Nanobiotechnology; 2020 Jan; 18(1):10. PubMed ID: 31918721
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Gao Z; Li Z; Yan J; Wang P
Drug Des Devel Ther; 2017; 11():2595-2604. PubMed ID: 28919710
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab-conjugated nanoparticles composed of poly(butylene adipate-
Varshosaz J; Ghassami E; Noorbakhsh A; Minaiyan M; Jahanian-Najafabadi A
IET Nanobiotechnol; 2019 Oct; 13(8):829-833. PubMed ID: 31625523
[TBL] [Abstract][Full Text] [Related]
36. Barbaloin loaded polydopamine-polylactide-TPGS (PLA-TPGS) nanoparticles against gastric cancer as a targeted drug delivery system: Studies in vitro and in vivo.
Wang YR; Yang SY; Chen GX; Wei P
Biochem Biophys Res Commun; 2018 Apr; 499(1):8-16. PubMed ID: 29534962
[TBL] [Abstract][Full Text] [Related]
37. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
[TBL] [Abstract][Full Text] [Related]
38. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
[TBL] [Abstract][Full Text] [Related]
40. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.
Eto K; Iwatsuki M; Watanabe M; Ishimoto T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Int J Cancer; 2015 Apr; 136(7):1537-45. PubMed ID: 25159729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
